| Literature DB >> 2123430 |
T M Roy1, V L Broadstone, H R Peterson, H L Snider, J Cyrus, R Fell, A H Rothchild, E Samols, M A Pfeifer.
Abstract
Because some aldose reductase inhibitor studies have demonstrated clinical improvement in scored neurological signs and symptoms of diabetic neuropathy, a prospective study of the effect on cardiovascular performance of sorbinil 250 mg/day for 12 months was conducted on patients with diabetic autonomic neuropathy who were free of atherosclerotic coronary artery disease and/or cardiomyopathy. After 1 year of treatment, the study group (n = 14) demonstrated significant improvement in both the resting cardiac output (P = 0.02), and the maximal cardiac output (P = 0.03). This observation suggests that the use of an aldose reductase inhibitor may be useful in treating suboptimal cardiovascular performance in patients with diabetic cardiac autonomic neuropathy.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2123430 DOI： 10.1016/0168-8227(90)90086-9
Source DB: PubMed Journal: Diabetes Res Clin Pract ISSN： 0168-8227 Impact factor: 5.602